Merck's 21-Valent Pneumococcal Conjugate Vaccine Gets FDA's Priority Review
The FDA has accepted for Priority Review the BLA for V116, an investigational 21-valent pneumococcal conjugate vaccine for adults.
Source: empr.com
Page 37 - Breakthrough Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Breakthrough Therapy Today - Breaking & Trending Today
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
TORONTO, Dec. 18, 2023 -- Revive Therapeutics Ltd. , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to...
Source: marketscreener.com
NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
Study May Proceed letter received from FDAPotential to initiate registrational study in 2024RADNOR, Pa., Dec. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. , a clinical-stage...
Source: marketscreener.com
GSK : Jemperli (dostarlimab) plus Zejula (niraparib) combination significantly improved progression-free survival in primary advanced or recurrent endometrial cancer in RUBY Part 2 Phase III trial - Form 6-K -December 18, 2023 at 06:38 am EST
A1192x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER...
Source: marketscreener.com
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
Investigational New Drug Submission Planned for GFH375/VS-7375 in H1 2024 No FDA Approved Therapies Available Targeting KRAS G12D, the Most Prevalent KRAS Mutation in Human Cancer ...
Source: marketscreener.com